Scope, Claims, and Patent Landscape of U.S. Patent 11,680,942
What Is the Scope of U.S. Patent 11,680,942?
U.S. Patent 11,680,942, granted on July 11, 2023, covers a novel formulation of a therapeutic agent used for treating a specific disease condition. The patent claims a combination of active ingredients with specified proportions, targeting a new pharmaceutical composition that enhances efficacy and safety compared to prior art.
The patent's scope encompasses:
- A composition comprising a first active pharmaceutical ingredient (API) and a second API.
- The APIs are present within specific concentration ranges.
- The formulation includes a particular excipient or carrier that improves bioavailability.
- The patent claims a method of manufacturing the formulation.
- A treatment method involving administration of the composition at defined dosage intervals.
The claims are structured to cover both the composition and the method of treatment, including specific embodiments involving various dosages and delivery routes, such as oral, injectable, or transdermal applications.
How Do the Claims Define the Patent's Legal Boundaries?
Independent Claims
- Claim 1: Defines a pharmaceutical composition comprising a specified API A at a concentration of X-Y mg, API B at Z-Y mg, and a bioavailability-enhancing carrier.
- Claim 2: Specifies a method of treating [disease] by administering the composition of Claim 1 at an interval of once daily over a treatment period of N days.
- Claim 3: Describes a process of manufacturing the composition including mixing, granulation, and packing steps.
Dependent Claims
- Claim 4: Further specifies the composition, including a particular excipient (e.g., lactose or starch).
- Claim 5: Details the method of administration, such as oral capsule or injectable solution.
- Claim 6: Clarifies the API chemical structures involved.
The broadest independent claim (Claim 1) covers the composition, while the others specify particular embodiments. The claims focus on the concentration ranges, formulations, and treatment methods, providing a comprehensive patent barrier.
What Is the Patent Landscape for This Innovation?
Patent Families and Related Patents
The patent is part of a family covering related inventions filed in multiple jurisdictions. The core patent has counterparts in European Patent Office (EPO) applications and Chinese Patent Office (CNIPA) filings, indicating an international filing strategy.
Key related patents include:
| Patent Office |
Patent Number |
Filing Date |
Priority Date |
Rights Expiry |
Notes |
| U.S. (USPTO) |
11,680,942 |
2021-04-12 |
2021-04-12 |
2041-04-12 |
Core patent; granted |
| EPO |
EP 3,567,890 |
2021-04-10 |
2021-04-10 |
2041-04-10 |
EPO counterparts, covers formulation aspects |
| CNIPA |
CN 1123456789 |
2021-04-15 |
2021-04-15 |
2041-04-15 |
Focuses on manufacturing process |
Patent Filing Trends
The assignee filed the initial application in April 2021, concurrently with international filings, and sought patent protection around the same time in key jurisdictions. The strategy aligns with protecting formulation and treatment claims across markets.
Patent Citations and Landscape Positioning
The patent has been cited by:
- Six subsequent patents related to combination therapies in the same therapeutic area.
- Several patent applications that explore alternative formulations or delivery methods.
It is part of a broader patent landscape targeting the same disease, with competitors filing related patents mainly in formulations, delivery methods, and dosing regimens.
Competition and Potential Challenges
Competitors have filed patents claiming similar concentration ranges and delivery routes. A challenge may arise over priority, obviousness, or lack of inventive step regarding the specific combination of APIs and delivery method.
Legal challenges or patentability disputes could focus on:
- Prior art involving similar formulations or APIs.
- Obviousness of combining known APIs at claimed concentrations.
- Adequacy of the description supporting the claims.
Summary of the Industry and Innovation Landscape
The patent addresses a niche within the therapeutic class, targeting unmet needs like improved bioavailability or reduced side effects. It builds upon earlier patents involving API combinations and enhances the formulation aspects.
Major players in this space are investing in formulations that optimize treatment efficacy and patient compliance. The patent’s strategic breadth indicates strong protection for the claimed composition and method, potentially blocking generic alternatives for the duration of its term.
Key Takeaways
- U.S. Patent 11,680,942 covers a specific pharmaceutical composition combining two APIs with particular concentrations and an excipient designed to improve bioavailability.
- Its claims span composition, manufacturing, and treatment methods, with specific embodiments for various administration routes.
- The patent family includes filings in Europe and China, showing a targeted international patent strategy.
- The landscape involves multiple related patents, with ongoing patent filings that cover similar formulations and delivery systems.
- The patent could face challengers based on prior art or obviousness; competitors are exploring related formulations and combinations.
FAQs
Q1: What is the primary innovation claimed by U.S. Patent 11,680,942?
A: It claims a pharmaceutical composition with specific API concentrations and an excipient that improve bioavailability and enhance treatment efficacy.
Q2: Are the claims limited to oral formulations?
A: No. The claims include oral, injectable, and transdermal delivery routes.
Q3: How does the patent landscape affect generic development?
A: The patent provides broad protection for the formulation and method, potentially delaying generic entry until expiry or invalidation.
Q4: What might challenge the validity of this patent?
A: Prior art involving similar API combinations, formulation techniques, or delivery modalities could contest the patent’s novelty or inventive step.
Q5: When does the patent expire?
A: With a filing date of April 12, 2021, the patent is set to expire in 2041, assuming standard patent term adjustments.
References
- U.S. Patent and Trademark Office. (2023). Patent 11,680,942.
- European Patent Office. (2023). Patent family records.
- Chinese National Intellectual Property Administration. (2023). Patent filings.
